Other languages NextCure, Inc.

Equities

NXTC

US65343E1082

Market Closed - Nasdaq Other stock markets 16:30:01 2024-05-03 EDT			5-day change	1st Jan Change
1.53 ^USD	+2.68%		+13.33%	+34.21%

05-02	NextCure, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-08	NextCure, Inc. and LigaChem Biosciences, Inc. Present Preclinical Data on B7-H4 Antibody Drug Conjugate At AACR 2024	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

NextCure, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-02
NextCure, Inc. and LigaChem Biosciences, Inc. Present Preclinical Data on B7-H4 Antibody Drug Conjugate At AACR 2024	04-08
NextCure, Inc. Appoints Rakesh Dixit to Scientific Advisory Board	04-04
NextCure, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-21
Top Premarket Decliners	02-27
NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders	01-18
Nextcure, Inc. Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury	12-21
Nextcure, Inc. Provides Year-End Clinical Pipeline Updates	12-14
NextCure, Inc. Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML	11-15
NextCure, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-02
NextCure, Inc. Announces Presentation of New Preclinical Data Demonstrate Treatment with NC605	23-10-17
NextCure Says Preclinical Data of NC181 for Alzheimer's Disease Shows Amyloid Clearance	23-09-26
NextCure, Inc. Presents Preclinical Data on Nc181, A Novel Therapeutic Candidate Targeting Apoe4, for the Treatment of Alzheimer's Disease	23-09-26
NextCure Reports Preclinical Data Show Potential NC605 Application in Bone Disease Treatment	23-09-05
NextCure, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03
NextCure, Inc. Announces Resignation of Garry A. Nicholson as from the Board of Directors	23-07-19
NextCure, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04
NextCure, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-02
NextCure, Inc. and LegoChem Biosciences Enter into Collaboration and Co-Development Agreement to Develop Antibody Drug Conjugates	22-11-15
NextCure Presents Initial Data from Clinical Trial of NC762 and a Trial in Progress Poster for NC410 Combo at the 2022 Society for Immunotherapy of Cancer Annual Meeting	22-11-07

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages NextCure, Inc.

Equities

NXTC

US65343E1082

Other languages

Filters